Compare FEMY & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEMY | VNRX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2M | 31.9M |
| IPO Year | 2021 | 2012 |
| Metric | FEMY | VNRX |
|---|---|---|
| Price | $0.53 | $0.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $6.83 | $2.50 |
| AVG Volume (30 Days) | 438.0K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.60 | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,629,108.00 | $1,233,511.00 |
| Revenue This Year | $64.02 | $60.84 |
| Revenue Next Year | $147.19 | $404.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 51.97 | ★ 59.10 |
| 52 Week Low | $0.31 | $0.17 |
| 52 Week High | $1.76 | $0.94 |
| Indicator | FEMY | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 38.64 |
| Support Level | $0.33 | $0.17 |
| Resistance Level | $0.57 | $0.33 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 50.25 | 33.37 |
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.